Trial Outcomes & Findings for Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) (NCT NCT03852472)

Last Updated: 2025-03-17

Results Overview

The percentage of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 in the ITT1 population using the NRI-CMH Test. A response was defined as a reduction of at least 50 in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count compared with baseline. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1. NRI- non-responder imputation; CMH- Cochran-Mantel-Haenszel. Percentage values have been reported as opposed to proportion values to allow for statistical analyses.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

435 participants

Primary outcome timeframe

Baseline to Week 12

Results posted on

2025-03-17

Participant Flow

Participant milestones

Participant milestones
Measure	Group A Period 1- Placebo BID for 12 Weeks	Group B Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Group C Avacopan 30 mg twice daily (BID) for Period 1+2 of the study	Placebo to Avacopan 10 mg Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.	Placebo to Avacopan 30 mg Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.
Period 1 - 12 Weeks STARTED	130	134	134	0	0
Period 1 - 12 Weeks Excluded Site 138 Subjects From ITT1	13	11	13	0	0
Period 1 - 12 Weeks COMPLETED	109	108	109	0	0
Period 1 - 12 Weeks NOT COMPLETED	21	26	25	0	0
Period 2 - Week 44 STARTED	0	108	108	56	53
Period 2 - Week 44 Excluded Site 138 Subjects From ITT2	0	7	9	3	6
Period 2 - Week 44 Completed Week 36	0	71	79	41	36
Period 2 - Week 44 Completed Week 44	0	70	75	39	35
Period 2 - Week 44 COMPLETED	0	70	75	39	35
Period 2 - Week 44 NOT COMPLETED	0	38	33	17	18

Reasons for withdrawal

Reasons for withdrawal
Measure	Group A Period 1- Placebo BID for 12 Weeks	Group B Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Group C Avacopan 30 mg twice daily (BID) for Period 1+2 of the study	Placebo to Avacopan 10 mg Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.	Placebo to Avacopan 30 mg Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.
Period 1 - 12 Weeks Withdrawal by Subject	8	10	7	0	0
Period 1 - 12 Weeks Subject noncompliance with dosing or diary completion	0	1	3	0	0
Period 1 - 12 Weeks Lost to Follow-up	5	5	7	0	0
Period 1 - 12 Weeks Noncompliance with the protocol	2	0	4	0	0
Period 1 - 12 Weeks At the discretion of the investigator or sponsor for any reason	0	3	0	0	0
Period 1 - 12 Weeks Adverse Event	4	6	4	0	0
Period 1 - 12 Weeks Reason not stated	2	1	0	0	0
Period 2 - Week 44 Withdrawal by Subject	0	22	15	10	10
Period 2 - Week 44 Subject noncompliance with dosing or diary completion	0	2	1	1	0
Period 2 - Week 44 Lost to Follow-up	0	8	12	1	2
Period 2 - Week 44 Noncompliance with the protocol	0	2	1	0	0
Period 2 - Week 44 At the discretion of the investigator or sponsor for any reason	0	1	3	2	3
Period 2 - Week 44 Adverse Event	0	3	1	2	2
Period 2 - Week 44 COVID-19 Related	0	0	0	1	0
Period 2 - Week 44 Reason not stated	0	0	0	0	1

Baseline Characteristics

Baseline characteristic value is not available for all patients.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Group A n=130 Participants Period 1- Placebo BID for 12 Weeks	Group B n=134 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Group C n=134 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study	Total n=398 Participants Total of all reporting groups
Age, Continuous	36.9 years STANDARD_DEVIATION 11.87 • n=130 Participants	36.0 years STANDARD_DEVIATION 12.05 • n=134 Participants	36.8 years STANDARD_DEVIATION 11.57 • n=134 Participants	36.6 years STANDARD_DEVIATION 11.81 • n=398 Participants
Sex: Female, Male Female	23 Participants n=130 Participants	30 Participants n=134 Participants	28 Participants n=134 Participants	81 Participants n=398 Participants
Sex: Female, Male Male	107 Participants n=130 Participants	104 Participants n=134 Participants	106 Participants n=134 Participants	317 Participants n=398 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	31 Participants n=130 Participants	22 Participants n=134 Participants	39 Participants n=134 Participants	92 Participants n=398 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	99 Participants n=130 Participants	112 Participants n=134 Participants	95 Participants n=134 Participants	306 Participants n=398 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=130 Participants	0 Participants n=134 Participants	0 Participants n=134 Participants	0 Participants n=398 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=130 Participants	0 Participants n=134 Participants	0 Participants n=134 Participants	0 Participants n=398 Participants
Race (NIH/OMB) Asian	0 Participants n=130 Participants	1 Participants n=134 Participants	0 Participants n=134 Participants	1 Participants n=398 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	1 Participants n=130 Participants	2 Participants n=134 Participants	0 Participants n=134 Participants	3 Participants n=398 Participants
Race (NIH/OMB) Black or African American	43 Participants n=130 Participants	46 Participants n=134 Participants	34 Participants n=134 Participants	123 Participants n=398 Participants
Race (NIH/OMB) White	83 Participants n=130 Participants	82 Participants n=134 Participants	96 Participants n=134 Participants	261 Participants n=398 Participants
Race (NIH/OMB) More than one race	0 Participants n=130 Participants	0 Participants n=134 Participants	2 Participants n=134 Participants	2 Participants n=398 Participants
Race (NIH/OMB) Unknown or Not Reported	3 Participants n=130 Participants	3 Participants n=134 Participants	2 Participants n=134 Participants	8 Participants n=398 Participants
Height	166.69 cm STANDARD_DEVIATION 8.696 • n=129 Participants • Baseline characteristic value is not available for all patients.	168.67 cm STANDARD_DEVIATION 9.852 • n=134 Participants • Baseline characteristic value is not available for all patients.	167.66 cm STANDARD_DEVIATION 9.021 • n=134 Participants • Baseline characteristic value is not available for all patients.	167.69 cm STANDARD_DEVIATION 9.221 • n=397 Participants • Baseline characteristic value is not available for all patients.
Weight	102.48 kg STANDARD_DEVIATION 23.425 • n=130 Participants	103.02 kg STANDARD_DEVIATION 27.817 • n=134 Participants	103.46 kg STANDARD_DEVIATION 28.601 • n=134 Participants	102.99 kg STANDARD_DEVIATION 26.678 • n=398 Participants
BMI	36.87 kg/m² STANDARD_DEVIATION 8.824 • n=129 Participants • Baseline characteristic value is not available for all patients.	36.14 kg/m² STANDARD_DEVIATION 8.728 • n=134 Participants • Baseline characteristic value is not available for all patients.	36.75 kg/m² STANDARD_DEVIATION 9.384 • n=134 Participants • Baseline characteristic value is not available for all patients.	36.58 kg/m² STANDARD_DEVIATION 8.969 • n=397 Participants • Baseline characteristic value is not available for all patients.
Hurley Stage of HS Stage II	85 Participants n=130 Participants	84 Participants n=134 Participants	87 Participants n=134 Participants	256 Participants n=398 Participants
Hurley Stage of HS Stage III	45 Participants n=130 Participants	50 Participants n=134 Participants	47 Participants n=134 Participants	142 Participants n=398 Participants
HS Disease Duration from Time of Diagnosis	11.06 years STANDARD_DEVIATION 10.275 • n=130 Participants	10.64 years STANDARD_DEVIATION 8.733 • n=134 Participants	11.21 years STANDARD_DEVIATION 9.521 • n=134 Participants	10.97 years STANDARD_DEVIATION 9.502 • n=398 Participants
Number of AN Count	11.6 abscess and inflammatory nodules STANDARD_DEVIATION 9.83 • n=130 Participants	13.5 abscess and inflammatory nodules STANDARD_DEVIATION 13.41 • n=134 Participants	12.3 abscess and inflammatory nodules STANDARD_DEVIATION 9.62 • n=134 Participants	12.5 abscess and inflammatory nodules STANDARD_DEVIATION 11.10 • n=398 Participants
Number of Draining Fistulae	2.8 Draining Fistulae STANDARD_DEVIATION 3.83 • n=130 Participants	3.2 Draining Fistulae STANDARD_DEVIATION 4.15 • n=134 Participants	2.4 Draining Fistulae STANDARD_DEVIATION 3.73 • n=134 Participants	2.8 Draining Fistulae STANDARD_DEVIATION 3.91 • n=398 Participants
IHS4 Score	29.6 score on a scale STANDARD_DEVIATION 29.34 • n=130 Participants	33.8 score on a scale STANDARD_DEVIATION 31.95 • n=134 Participants	30.0 score on a scale STANDARD_DEVIATION 25.02 • n=134 Participants	31.2 score on a scale STANDARD_DEVIATION 28.90 • n=398 Participants
Subject's Global Assessment of Skin Pain NRS	5.6 score on a scale STANDARD_DEVIATION 2.52 • n=126 Participants • Baseline characteristic value is not available for all patients.	5.3 score on a scale STANDARD_DEVIATION 2.54 • n=129 Participants • Baseline characteristic value is not available for all patients.	5.2 score on a scale STANDARD_DEVIATION 2.47 • n=127 Participants • Baseline characteristic value is not available for all patients.	5.4 score on a scale STANDARD_DEVIATION 2.51 • n=382 Participants • Baseline characteristic value is not available for all patients.
Previous TNF Inhibitor Use Yes	35 Participants n=130 Participants	38 Participants n=134 Participants	36 Participants n=134 Participants	109 Participants n=398 Participants
Previous TNF Inhibitor Use No	95 Participants n=130 Participants	96 Participants n=134 Participants	98 Participants n=134 Participants	289 Participants n=398 Participants
Previously Started (allowed) Concomitant Antibiotic Yes	8 Participants n=130 Participants	9 Participants n=134 Participants	7 Participants n=134 Participants	24 Participants n=398 Participants
Previously Started (allowed) Concomitant Antibiotic No	122 Participants n=130 Participants	125 Participants n=134 Participants	127 Participants n=134 Participants	374 Participants n=398 Participants

PRIMARY outcome

Timeframe: Baseline to Week 12

Outcome measures

Outcome measures
Measure	Placebo n=130 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=134 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg n=134 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.	30.8 percentage of participants	22.4 percentage of participants	35.1 percentage of participants

SECONDARY outcome

Timeframe: Baseline to Week 12

The Change from Baseline in total AN (abscess and inflammatory nodule) count at Week 12 using MMRM and OC in the ITT1 population. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1. MMRM - mixed effects model for repeated measures; OC- observed case

Outcome measures

Outcome measures
Measure	Placebo n=110 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=110 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg n=110 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Change From Baseline in Total AN Count at Week 12	-3.1 percentage of ANs Standard Deviation 8.57	-3.4 percentage of ANs Standard Deviation 10.58	-5.1 percentage of ANs Standard Deviation 8.41

SECONDARY outcome

Timeframe: Baseline to Week 12

NRS30 = The number of responders achieving at least 30% reduction and at least 1 unit reduction from baseline in the subject's global assessment of skin pain score. Percentage is based on the number of subjects with a baseline pain score of at least 3 in each treatment group. Weekly averages of daily pain will be calculated based on subjects' daily diary recording of the worst pain experienced in the previous 24 hours. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1. NRI- non-responder imputation

Outcome measures

Outcome measures
Measure	Placebo n=105 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=104 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg n=104 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Number of Responders Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in the Subject's Global Assessment of Skin Pain (NRS30) in Subjects With a Baseline NRS of at Least 3, Evaluated at Week 12	26 number of responders	23 number of responders	17 number of responders

SECONDARY outcome

Timeframe: Day 1

The Area under the curve from Time 0-3hrs (AUC 0-3hrs) of Metabolite M1 plasma concentration on Day 1 in the PK population. PK- pharmacokinetics

Outcome measures

Outcome measures
Measure	Placebo n=28 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=29 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Area Under the Curve From Time 0-3hrs (AUC 0-3hrs) of Metabolite M1 Plasma Concentration on Day 1	18.0 h*ng/mL Standard Deviation 8.23	50.3 h*ng/mL Standard Deviation 34.3	—

SECONDARY outcome

Timeframe: Baseline and Week 12

The number of responders With Baseline Hurley Stage II Who Achieved an Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12 using the NRI-CMH Test in the ITT1 population. Hurley Stage II disease is defined as having 1 or more widely separated recurrent abscesses with tract formation and scars. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

Outcome measures

Outcome measures
Measure	Placebo n=85 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=84 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg n=87 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Number of Responders With Baseline Hurley Stage II Who Achieved an AN Count of 0, 1, or 2 at Week 12	29 number of responders	15 number of responders	20 number of responders

SECONDARY outcome

Timeframe: Baseline and Week 12

The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1. IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + \[number of draining tunnels (fistulae/sinuses) multiplied by 4\]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS. IHS4- International HS Severity Scoring System

Outcome measures

Outcome measures
Measure	Placebo n=110 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=110 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg n=110 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Change of IHS4 Score Relative to Baseline at Week 12.	-6.4 score on a scale Standard Deviation 16.99	-7.9 score on a scale Standard Deviation 22.14	-9.8 score on a scale Standard Deviation 15.69

SECONDARY outcome

Timeframe: Baseline and Week 12

A reduction in AN signifies improvement. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

Outcome measures

Outcome measures
Measure	Placebo n=110 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=110 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg n=110 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Change From Baseline in Inflammatory Nodule Count at Week 12	-2.4 count of inflammatory nodules Standard Deviation 7.48	-2.5 count of inflammatory nodules Standard Deviation 9.17	-3.9 count of inflammatory nodules Standard Deviation 7.06

SECONDARY outcome

Timeframe: Baseline and Week 12

A reduction in abscess count signifies improvement. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

Outcome measures

Outcome measures
Measure	Placebo n=110 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=110 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg n=110 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Change From Baseline in Abscess Count at Week 12	-0.8 count of abscesses Standard Deviation 3.68	-0.8 count of abscesses Standard Deviation 3.38	-1.2 count of abscesses Standard Deviation 2.73

SECONDARY outcome

Timeframe: Baseline and Week 2, Week 4, Week 8 and Week 12

The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

Outcome measures

Outcome measures
Measure	Placebo n=130 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=134 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg n=134 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Change From Baseline in Draining Fistula Count at Week 12 Week 2	-0.3 Draining Fistulae Standard Deviation 2.23	-0.5 Draining Fistulae Standard Deviation 2.22	-0.4 Draining Fistulae Standard Deviation 1.79
Change From Baseline in Draining Fistula Count at Week 12 Week 4	-0.5 Draining Fistulae Standard Deviation 2.17	-0.8 Draining Fistulae Standard Deviation 2.88	-0.4 Draining Fistulae Standard Deviation 2.16
Change From Baseline in Draining Fistula Count at Week 12 Week 8	-0.4 Draining Fistulae Standard Deviation 1.82	-0.9 Draining Fistulae Standard Deviation 2.93	-0.6 Draining Fistulae Standard Deviation 2.03
Change From Baseline in Draining Fistula Count at Week 12 Week 12	-0.6 Draining Fistulae Standard Deviation 2.11	-0.9 Draining Fistulae Standard Deviation 2.57	-0.5 Draining Fistulae Standard Deviation 1.87

SECONDARY outcome

Timeframe: Baseline and Week 2, Week 4, Week 8 and Week 12

Twelve body areas will be evaluated to calculate the Sartorius and modified Sartorius scores: left and right axillae, left and right inframammary areas, intermammary area, left and right buttocks, left and right inguinocrural folds, perianal area, perineal area, and other. The presence of nodules, abscesses, fistulae, scars, and other findings will be recorded. The longest distance between two lesions and whether lesions are separated by normal skin is recorded. A score of 4 indicates the least severe disease, and higher scores indicate increasingly severe disease. There is no upper limit in the score. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

Outcome measures

Outcome measures
Measure	Placebo n=130 Participants Placebo BID for 12 Weeks	Avacopan 10 mg n=134 Participants Avacopan 10 mg twice daily (BID) for Period 1+2 of the study	Avacopan 30 mg n=134 Participants Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
Change From Baseline to Week 12 in the Modified Sartorius Score to Quantify the Severity Change of HS Week 4	-5.7 score on a scale Standard Deviation 23.70	-7.2 score on a scale Standard Deviation 22.84	-6.5 score on a scale Standard Deviation 21.37
Change From Baseline to Week 12 in the Modified Sartorius Score to Quantify the Severity Change of HS Week 8	-9.8 score on a scale Standard Deviation 32.60	-11.5 score on a scale Standard Deviation 23.64	-10.4 score on a scale Standard Deviation 26.43
Change From Baseline to Week 12 in the Modified Sartorius Score to Quantify the Severity Change of HS Week 2	-3.0 score on a scale Standard Deviation 21.02	-3.5 score on a scale Standard Deviation 16.68	-6.3 score on a scale Standard Deviation 17.72
Change From Baseline to Week 12 in the Modified Sartorius Score to Quantify the Severity Change of HS Week 12	-11.2 score on a scale Standard Deviation 35.69	-12.6 score on a scale Standard Deviation 25.98	-14.4 score on a scale Standard Deviation 29.96

Adverse Events

Placebo Period 1

Serious events: 3 serious events

Other events: 22 other events

Deaths: 0 deaths

Avacopan 10 mg Period 1

Serious events: 3 serious events

Other events: 18 other events

Deaths: 0 deaths

Avacopan 30 mg Period 1

Serious events: 1 serious events

Other events: 15 other events

Deaths: 0 deaths

Placebo to Avacopan 10 mg Period 2

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Placebo to Avacopan 30 mg Period 2

Serious events: 1 serious events

Other events: 8 other events

Deaths: 0 deaths

Avacopan 10 mg Period 2

Serious events: 4 serious events

Other events: 21 other events

Deaths: 0 deaths

Avacopan 30 mg Period 2

Serious events: 2 serious events

Other events: 20 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo Period 1 n=129 participants at risk Subjects randomized to placebo during period 1	Avacopan 10 mg Period 1 n=134 participants at risk Avacopan 10 mg twice daily (BID) for Period 1 of the study	Avacopan 30 mg Period 1 n=135 participants at risk Avacopan 30 mg twice daily (BID) for Period 1 of the study	Placebo to Avacopan 10 mg Period 2 n=56 participants at risk Placebo population from Period 1 split into Placebo to Avacopan 10 mg twice daily (BID) for Period 2 of the study	Placebo to Avacopan 30 mg Period 2 n=52 participants at risk Placebo population from Period 1 split into Placebo to Avacopan 30 mg twice daily (BID) for Period 2 of the study	Avacopan 10 mg Period 2 n=108 participants at risk Avacopan 10 mg twice daily (BID) for Period 2 of the study	Avacopan 30 mg Period 2 n=109 participants at risk Avacopan 30 mg twice daily (BID) for Period 2 of the study
Skin and subcutaneous tissue disorders Hidradenitis	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.75% 1/134 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Gastrointestinal disorders Abdominal Pain	0.78% 1/129 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Gastrointestinal disorders Anal fistula	0.78% 1/129 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Infections and infestations Cellulitis	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.75% 1/134 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.74% 1/135 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.93% 1/108 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Gastrointestinal disorders Gastritis	0.78% 1/129 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Investigations Lipase increased	0.78% 1/129 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Psychiatric disorders Anxiety	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.75% 1/134 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Psychiatric disorders Depression	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.75% 1/134 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Psychiatric disorders Major depression	0.78% 1/129 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Infections and infestations Abscess neck	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.92% 1/109 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.93% 1/108 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Infections and infestations Corona virus infection	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.93% 1/108 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Gastrointestinal disorders Duodenal ulcer haemorrhage	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.93% 1/108 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.92% 1/109 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Psychiatric disorders Suicidal ideation	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	1.9% 1/52 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Investigations Tuberculin test false positive	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/134 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.93% 1/108 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively

Other adverse events

Other adverse events
Measure	Placebo Period 1 n=129 participants at risk Subjects randomized to placebo during period 1	Avacopan 10 mg Period 1 n=134 participants at risk Avacopan 10 mg twice daily (BID) for Period 1 of the study	Avacopan 30 mg Period 1 n=135 participants at risk Avacopan 30 mg twice daily (BID) for Period 1 of the study	Placebo to Avacopan 10 mg Period 2 n=56 participants at risk Placebo population from Period 1 split into Placebo to Avacopan 10 mg twice daily (BID) for Period 2 of the study	Placebo to Avacopan 30 mg Period 2 n=52 participants at risk Placebo population from Period 1 split into Placebo to Avacopan 30 mg twice daily (BID) for Period 2 of the study	Avacopan 10 mg Period 2 n=108 participants at risk Avacopan 10 mg twice daily (BID) for Period 2 of the study	Avacopan 30 mg Period 2 n=109 participants at risk Avacopan 30 mg twice daily (BID) for Period 2 of the study
Skin and subcutaneous tissue disorders Hidradenitis	13.2% 17/129 • Number of events 35 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	10.4% 14/134 • Number of events 15 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	8.9% 12/135 • Number of events 23 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	8.9% 5/56 • Number of events 6 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	15.4% 8/52 • Number of events 12 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	17.6% 19/108 • Number of events 30 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	17.4% 19/109 • Number of events 31 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Nervous system disorders Headache	3.1% 4/129 • Number of events 10 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	6.0% 8/134 • Number of events 8 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	3.0% 4/135 • Number of events 4 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	5.4% 3/56 • Number of events 4 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	1.9% 2/108 • Number of events 2 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.92% 1/109 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Gastrointestinal disorders Nausea	6.2% 8/129 • Number of events 8 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	2.2% 3/134 • Number of events 3 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	3.0% 4/135 • Number of events 4 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/52 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/108 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/109 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Infections and infestations Corona virus infection	0.00% 0/129 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.75% 1/134 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/135 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.00% 0/56 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	3.8% 2/52 • Number of events 2 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	6.5% 7/108 • Number of events 7 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	4.6% 5/109 • Number of events 5 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Infections and infestations Upper respiratory tract infection	3.9% 5/129 • Number of events 5 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	1.5% 2/134 • Number of events 2 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	3.0% 4/135 • Number of events 4 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	5.4% 3/56 • Number of events 3 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	1.9% 1/52 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	1.9% 2/108 • Number of events 2 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.92% 1/109 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively
Investigations Alanine aminotransferase increased	1.6% 2/129 • Number of events 2 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	3.0% 4/134 • Number of events 4 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	0.74% 1/135 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	5.4% 3/56 • Number of events 3 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	1.9% 1/52 • Number of events 1 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	4.6% 5/108 • Number of events 6 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively	2.8% 3/109 • Number of events 4 • All subjects in Period 1 +2 of the study through completion of study an average of 44 weeks The Safety 1 population was the same as the ITT1 except subjects were assigned to the treatment they received; 1 subject randomized to the placebo group received Avacopan 30 mg during period 1. Thus, this subject is counted in the groups "Avacopan 30 mg Period 1" and "Avacopan 30 mg Period 2" instead of in groups "Placebo Period 1" and "Placebo to Avacopan 30 mg Period 2", respectively

Additional Information

Study Director

Chemocentryx

Phone: 650-210-2900

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place